FrancophonIA/ELRC3.0 huggingface dataset:
English: Given that raltegravir is metabolised primarily via UGT1A1, caution should also be used when co-administering DUTREBIS with other strong inducers of UGT1A1.
Slovenian: Raltegravir se presnavlja predvsem z UGT1A1, zato je v primeru sočasne uporabe zdravila DUTREBIS z drugimi močnimi induktorji UGT1A1 potrebna previdnost.
English: • increased appetite; diabetes; high sugar levels in the blood; excessive thirst; severe weight loss; body fat disorder
Slovenian: • povečan apetit, sladkorna bolezen, visok krvni sladkor, prekomerna žeja, močno hujšanje,
English: Pharmacokinetic parameters were not altered by diminishing hepatic function; therefore, no dose adjustment for lamivudine is required for patients with impaired hepatic function.
Slovenian: Zmanjševanje delovanja jeter ni vplivalo na farmakokinetične parametre, zato bolnikom z okvarjenim delovanjem jeter odmerka lamivudina ni treba prilagoditi.
English: The combination of lamivudine with cladribine is not-recommended (see section 4.5).
Slovenian: Kombinacija lamivudina in kladribina ni priporočljiva (glejte poglavje 4.5).
English: Therefore, when DUTREBIS is co-administered with calcium carbonate containing antacids no dose adjustment is required.
Slovenian: Zato pri sočasni uporabi zdravila DUTREBIS in antacidov, ki vsebujejo kalcijev karbonat, odmerka ni treba prilagoditi.
English: Tell your doctor, pharmacist or nurse immediately if you notice any symptoms of infection or other symptoms such as:
Slovenian: Nemudoma obvestite zdravnika, farmacevta ali medicinsko sestro, če opazite kateri koli simptom okužbe ali kateri koli drug simptom, na primer:
English: Zidovudine and stavudine maintain their antiretroviral activities against lamivudine-resistant HIV-1.
Slovenian: Zidovudin in stavudin ohranita svoje protiretrovirusno delovanje proti HIV-1, ki je odporen na lamivudin.
English: In clinical studies of treatment-experienced patients receiving raltegravir, rash, irrespective of causality, was more commonly observed with regimens containing raltegravir and darunavir compared to those containing raltegravir without darunavir or darunavir without raltegravir.
Slovenian: V kliničnih študijah so pri že zdravljenih bolnikih, ki so prejemali raltegravir, izpuščaj (ne glede na vzrok) pogosteje opažali pri bolnikih, ki so se zdravili s kombinacijo raltegravirja in darunavirja, kot pri bolnikih, ki so prejemali raltegravir brez darunavirja ali darunavir brez raltegravirja.
English: • trimethoprim - used to treat infections.
Slovenian: • trimetoprim - uporablja se za zdravljenje okužb
English: Do not stop taking DUTREBIS without your doctor's advice.
Slovenian: Ne prenehajte jemati zdravila DUTREBIS, če vam tega ne naroči zdravnik.
English: • blood test showing decreased count of platelets in blood (a kind of cell that helps blood clot); blood test showing reduced kidney function; increased muscle enzyme in blood; sugar present in urine; red blood cells present in urine; weight gain; increase in waist size; decreased blood protein (albumin); increase in time for blood to clot; blood test showing
Slovenian: • izvid krvi, ki kaže zmanjšano število trombocitov v krvi (vrsta krvnih celic, ki pomaga pri strjevanju krvi), izvid krvi, ki kaže zmanjšano delovanje ledvic, zvišanje mišičnega encima v krvi, sladkor v urinu, rdeče krvne celice v urinu, povečanje telesne mase, povečan obseg pasu, znižanje beljakovin (albumina) v krvi, podaljšan čas strjevanja krvi, izvid krvi, ki kaže majhno število rdečih krvnih celic (anemija)
English: The most common adverse reactions reported during treatment with lamivudine are headache, nausea, malaise, fatigue, nasal signs and symptoms, diarrhoea and cough.
Slovenian: Najpogostejši neželeni učinki, o katerih so poročali med zdravljenjem z lamivudinom, so glavobol, navzea, splošno slabo počutje, utrujenost, znaki in simptomi v nosu, driska in kašelj.
English: Patients with a prior history of virological failure were not excluded and the number of previous antiretroviral therapies was not limited.
Slovenian: Število predhodnih protiretrovirusnih terapij ni bilo omejeno.
English: Physicians should refer to current HIV treatment guidelines for the optimal management of HIV infection in patients co-infected with HBV.
Slovenian: Zdravniki morajo za optimalno obvladovanje okužbe s HIV pri bolnikih, sočasno okuženih s HBV, upoštevati trenutno veljavne smernice za zdravljenje HIV.
English: Tell your doctor immediately if you have any of the following signs of lactic acidosis, or any other
Slovenian: Zdravnika morate nemudoma obvestiti, če se vam pojavi kateri od naslednjih znakov laktacidoze, ali kateri koli drug simptom, ki vas skrbi:
English: Some people taking DUTREBIS, or similar medicines, may get a side effect called “lactic acidosis” and a swollen liver.
Slovenian: Pri nekaterih bolnikih, ki jemljejo zdravilo DUTREBIS ali podobna zdravila, se lahko razvije neželen učinek, imenovan "laktacidoza", skupaj z oteklostjo jeter.
English: In HIV-infected patients with severe immune deficiency at the time of institution of combination antiretroviral therapy (CART), an inflammatory reaction to asymptomatic or residual opportunistic pathogens may arise and cause serious clinical conditions, or aggravation of symptoms.
Slovenian: Pri bolnikih, okuženih s HIV, ki so v času uvedbe kombiniranega protiretrovirusnega zdravljenja imunsko zelo oslabeli, se lahko pojavi vnetna reakcija na asimptomatske ali rezidualne oportunistične patogene ter povzroči resna klinična stanja ali poslabšanje simptomov.
English: The pharmacokinetics of DUTREBIS in children under 6 years of age has not been established.
Slovenian: Farmakokinetika zdravila DUTREBIS pri otrocih, mlajših od 6 let, ni določena.
English: STARTMRK Study
Slovenian: Študija STARTMRK
English: Possible interaction between lamivudine and cladribine due to inhibition of intracellular phosphorylation of cladribine by lamivudine.
Slovenian: Možna medsebojna delovanja med lamivudinom in kladribinom zaradi zaviranja znotrajcelične fosforilacije kladribina z
English: As demonstrated in healthy volunteers administered single oral doses of raltegravir in the fasted state, raltegravir AUC and Cmax increase dose proportionally over the dose range 100 mg to 1,600 mg.
Slovenian: Pri zdravih prostovoljcih, ki so prejeli enkraten peroralni odmerek raltegravirja na tešče, se vrednosti AUC in Cmax v razponu odmerkov od 100 mg do 1.600 mg povečujejo sorazmerno z odmerkom.
English: Tmax was not significantly affected by renal function.
Slovenian: Delovanje ledvic ni pomembno vplivalo na tmax.
English: At the NOAEL, systemic exposure was similar to that at the clinical dose of 400 mg twice daily.
Slovenian: Pri odmerkih, pri katerih ni bilo opaziti neželenih učinkov (NOAEL), je bila sistemska izpostavljenost podobna kot pri kliničnem odmerku 400 mg dvakrat na dan.
English: From the clinical studies, a large proportion of patients used atazanavir and / or tenofovir, both agents that result in increases in raltegravir plasma levels, in the optimised background regimens.
Slovenian: V kliničnih študijah je velik delež bolnikov v okviru optimiziranega osnovnega zdravljenja (OBT - optimized background therapy) uporabljal atazanavir in/ali tenofovir, zdravili, ki povečata koncentracijo raltegravirja v plazmi.
English: DUTREBIS should not be given in patients with a creatinine clearance of <50 ml/min.
Slovenian: Zdravila DUTREBIS ne smejo prejemati bolniki z očistkom kreatinina < 50 ml/min.
English: The raltegravir component in DUTREBIS (300 mg raltegravir) fixed-dose combination tablet was not bioequivalent with respect to C12, however, based on PK/PD modelling, no clinically meaningful differences in raltegravir exposure are expected.
Slovenian: Ugotovljeno je, da raltegravir v tabletah s fiksno kombinacijo odmerkov DUTREBIS (300 mg raltegravirja) ni bil bioekvivalenten glede na C12, vendar glede na farmakokinetično/farmakodinamično modeliranje ni pričakovati, da bi se izpostavljenost raltegravirju klinično pomembno razlikovala.
English: • increased liver blood tests; abnormal white blood cells; increased fat levels in blood (such as cholesterol and triglycerides); increased level of enzyme from salivary glands or pancreas
Slovenian: • zvišanje vrednosti krvnih preiskav delovanja jeter, nenormalne bele krvne celice, zvišana koncentracija maščob v krvi (na primer holesterola in trigliceridov), zvišane vrednosti encimov žlez slinavk ali trebušne slinavke
English: Raltegravir readily crossed the placenta in rats, but did not penetrate the brain to any appreciable extent.
Slovenian: Pri podganah raltegravir zlahka prehaja skozi placento, v možgane pa ne prehaja v pomembnejšem
English: Zidovudine has no effect on the pharmacokinetics of lamivudine (see section 5.2).
Slovenian: Zidovudin ne vpliva na farmakokinetiko lamivudina (glejte
English: DUTREBIS should not be used when co-administered with rifampicin.
Slovenian: Zdravila DUTREBIS se ne sme uporabljati sočasno z rifampicinom.
English: The pharmacokinetic properties of lamivudine have been determined in a small group of HIV-1-infected adults with impaired renal function.
Slovenian: Farmakokinetične lastnosti lamivudina so proučili v majhni skupini odraslih, okuženih s HIV-1, z
English: The safety and efficacy of lamivudine and raltegravir have not been established in patients with severe underlying liver disorders.
Slovenian: Varnost in učinkovitost lamivudina in raltegravirja pri bolnikih s hudo boleznijo jeter nista dokazani.
English: If this is noticed later than 6 hours of the time it is usually taken, the missed dose should not be taken and the patient should resume the usual dosing schedule.
Slovenian: Če pa je od tedaj, ko ponavadi vzame zdravilo, minilo več kot 6 ur, pozabljenega odmerka ne sme vzeti, ampak mora nadaljevati po običajnem urniku jemanja.
English: Caution should be used when administering DUTREBIS in patients with a pre-existing history of depression or psychiatric
Slovenian: Previdnost je potrebna med uporabo zdravila DUTREBIS pri bolnikih, ki imajo v anamnezi depresijo ali psihiatrično bolezen.
English: Raltegravir in the fixed-dose combination tablet was not bioequivalent with respect to C12, however, based on PK/PD modelling, no clinically meaningful differences in raltegravir exposure are expected following administration of the fixed-dose combination tablet compared to administration of raltegravir as a single agent.
Slovenian: Raltegravir v tabletah s fiksno kombinacijo odmerkov ni bil bioekvivalenten glede na C12, vendar glede na farmakokinetično/farmakodinamično modeliranje ni pričakovati, da bi se izpostavljenost raltegravirju po uporabi tablet s fiksno kombinacijo odmerkov klinično pomembno razlikovala od izpostavljenosti po uporabi raltegravirja samega.
English: Patients with pre-existing liver dysfunction including chronic hepatitis have an increased frequency of liver function abnormalities during CART and should be monitored according to standard practice.
Slovenian: Pri bolnikih z obstoječo okvaro jeter, vključno s kroničnim hepatitisom, so nepravilnosti delovanja jeter med kombiniranim protiretrovirusnim zdravljenjem pogostejše; takšne bolnike je treba spremljati v skladu z običajno prakso.
English: If you notice after 6 hours, then skip the intake and take the next doses as
Slovenian: Če to ugotovite pozneje kot v 6 urah, izpustite odmerek zdravila in vzemite naslednji odmerek kot običajno.
English: The main adverse reactions reported are haematological disorders (anaemia, neutropenia), metabolic disorders (hyperlactatemia, hyperlipasemia).
Slovenian: Glavni poročani neželeni učinki so hematološke motnje (anemija, nevtropenija) in presnovne motnje (hiperlaktatemija, hiperlipazemija).
English: Co-administration of DUTREBIS with aluminium and/or magnesium antacids is not recommended (see section 4.5).
Slovenian: Sočasna uporaba zdravila DUTREBIS z aluminijevimi in/ali magnezijevimi antacidi ni priporočljiva (glejte poglavje 4.5).
English: Patient demographics (gender, age and race) and baseline characteristics were comparable between the group receiving raltegravir 400 mg twice daily and the group receiving efavirenz 600 mg at bedtime.
Slovenian: Demografske (spol, starost in rasa) in izhodiščne značilnosti bolnikov so bile med skupino, ki je prejemala 400 mg raltegravirja dvakrat na dan, in skupino, ki je prejemala 600 mg efavirenza pred
English: Raltegravir is approximately 83 % bound to human plasma protein over the concentration range of 2 to 10 µM.
Slovenian: Pri koncentracijah od 2 do 10 µM je vezava raltegravirja na beljakovine v plazmi približno 83 %.
English: Therefore, DUTREBIS should be used with caution in patients with severe hepatic impairment (see sections 4.2 and 5.2).
Slovenian: DUTREBIS je treba zato pri bolnikih s hudo okvaro jeter previdno uporabljati (glejte poglavji 4.2 in 5.2).
English: Thus the data indicate that the major mechanism of clearance of raltegravir in humans is UGT1A1-mediated glucuronidation.
Slovenian: Podatki torej kažejo, da je glukuronidacija z UGT1A1 pri človeku glavni mehanizem očistka raltegravirja.
English: It contains the active substances lamivudine and raltegravir:
Slovenian: Vsebuje zdravilni učinkovini lamivudin in raltegravir:
English: • acne; unusual hair loss or thinning; redness of skin; unusual distribution of fat on the body, this may include loss of fat from legs, arms, and face, and increase in abdomen fat; excessive sweating; night sweats; thickening and itching of the skin due to repeated
Slovenian: • akne, neobičajno izpadanje ali redčenje las, pordelost kože, nenavadna porazdelitev maščevja na telesu (to lahko obsega zmanjšanje maščevja na nogah, rokah in obrazu ter povečanje trebušne maščobe), prekomerno znojenje, nočno znojenje, zadebelitev in srbenje kože zaradi stalnega praskanja, poškodbe kože, suha koža
English: DUTREBIS should not be used in children below 6 years of age.
Slovenian: Zdravila DUTREBIS se ne sme uporabljati pri otrocih, mlajših od 6 let.
English: Co-administration of DUTREBIS with other agents that increase gastric pH (e.g., omeprazole and famotidine) may increase the rate of raltegravir absorption and result in increased plasma levels of raltegravir (see Table 1).
Slovenian: Sočasna uporaba zdravila DUTREBIS z drugimi zdravili, ki zvišujejo želodčni pH (npr. omeprazol ali famotidin), lahko poveča obseg absorpcije raltegravirja in tako poveča koncentracijo raltegravirja v plazmi (glejte preglednico 1).
English: Raltegravir was administered with an optimized background regimen.
Slovenian: Raltegravir so prejemali poleg optimalnega osnovnega režima zdravljenja.
English: Safety and efficacy of lamivudine have not been established in the presence of decompensated liver disease.
Slovenian: Varnost in učinkovitost lamivudina nista raziskani pri bolnikih z dekompenzirano boleznijo jeter.
English: The following adverse reactions were identified through post-marketing surveillance of raltegravir: thrombocytopenia, suicidal ideation, suicidal behaviour (particularly in patients with a pre-existing history of psychiatric illness), hepatic failure, Stevens Johnson syndrome, drug rash with eosinophilia and systemic symptoms (DRESS), rhabdomyolysis.
Slovenian: Med spremljanjem raltegravirja v obdobju trženja so ugotovili naslednje neželene učinke: trombocitopenijo, samomorilne misli, samomorilno vedenje (predvsem pri bolnikih, ki so v preteklosti že kdaj imeli psihiatrične motnje), odpoved jeter, Stevens-Johnsonov sindrom, izpuščaj z eozinofilijo in sistemskimi simptomi kot posledica zdravljenja z zdravilom (DRESS), rabdomiolizo.
English: • fat may be lost from the legs, arms or face; extra fat may build up around the tummy, breasts or internal organs; fatty lumps (sometimes called buffalo hump) may appear on the back of the neck.
Slovenian: • zmanjšanje maščevja na nogah, rokah in obrazu, dodatno maščevje se lahko nabere na trebuhu, prsih ali notranjih organih, na zadnji strani vratu se lahko pojavijo maščobne bule (temu včasih pravijo bivolja grba).
English: Talk to your doctor if you notice changes in your body shape.
Slovenian: Če opazite spremembe oblike telesa, se posvetujte z zdravnikom.
English: Raltegravir has been studied in 126 antiretroviral treatment-experienced HIV-1 infected children and adolescents 2 through 18 years of age, in combination with other antiretroviral agents in IMPAACT P1066 (see sections 5.1 and 5.2).
Slovenian: Raltegravir so v kombinaciji z drugimi protiretrovirusnimi učinkovinami preučili v študiji IMPAACT P1066 pri 126 otrocih in mladostnikih, okuženih z virusom HIV-1, starih od 2 do 18 let, ki so se že zdravili s protiretrovirusnimi učinkovinami (glejte poglavji 5.1 in 5.2).
English: There have been reports of mitochondrial dysfunction in HIV-negative infants exposed in utero and/or post-natally to nucleoside reverse transcriptase inhibitors.
Slovenian: Opisani so primeri motenega delovanja mitohondrijev pri HIV-negativnih dojenčkih, ki so bili in utero in/ali po rojstvu izpostavljeni nukleozidnim zaviralcem reverzne transkriptaze.
English: As DUTREBIS contains lamivudine and raltegravir, any interactions that have been identified with these agents individually, may occur with DUTREBIS.
Slovenian: Ker zdravilo DUTREBIS vsebuje lamivudin in raltegravir, se lahko med njegovo uporabo pojavi katero koli medsebojno delovanje, ugotovljeno za vsako od obeh učinkovin posamezno.
English: trimethoprim PK ↔ sulfamethoxazole PK ↔
Slovenian: FK trimetoprima ↔ FK sulfametoksazola ↔
English: The Genotypic Sensitivity Score (GSS) was defined as the total oral ARTs in the optimised background therapy (OBT) to which a patient's viral isolate showed genotypic sensitivity based upon genotypic resistance test. Enfuvirtide use in OBT in enfuvirtide-naïve patients was counted as one active drug in OBT.
Slovenian: Rezultat genotipske občutljivosti (GSS - Genotypic Sensitivity Score) je bil definiran kot skupno število peroralnih protiretrovirusnih zdravil pri optimiziranem osnovnem zdravljenju (OBT) na katera so bili izolati virusa pri testiranju genotipske odpornosti genotipsko občutljivi.
English: In adults, there were no clinically important pharmacokinetic differences between patients with moderate hepatic insufficiency and healthy subjects.
Slovenian: Farmakokinetika se pri odraslih bolnikih z zmerno jetrno insuficienco in zdravih osebah ni klinično pomembno razlikovala.
English: See section 4.4 regarding the need to administer raltegravir with another active agent.
Slovenian: Glede potrebe po uporabi raltegravirja skupaj z drugo učinkovino glejte poglavje 4.4.
English: Dose adjustment is not considered necessary in subjects with reduced UGT1A1 activity due to genetic polymorphism.
Slovenian: Osebam, ki imajo zaradi genetskega polimorfizma zmanjšano aktivnost UGT1A1, odmerka ni treba prilagoditi.
English: Co-administration of raltegravir with a calcium carbonate antacid decreased raltegravir plasma levels; however, this interaction is not considered clinically meaningful.
Slovenian: Sočasna uporaba raltegravirja z antacidom, ki vsebuje kalcijev karbonat, je zmanjšala koncentracijo raltegravirja v plazmi, vendar to medsebojno delovanje ne velja za klinično pomembno.
English: Similar AUC values for fed vs. fasted and somewhat lower Cmax values (23 % for raltegravir and 21 % for lamivudine) were observed with DUTREBIS.
Slovenian: V primerjavi med uporabo na poln in prazen želodec je za zdravilo DUTREBIS pokazala podobne vrednosti AUC in nekoliko nižje vrednosti Cmax (23 % za raltegravir in 21 % za lamivudin).
English: Efavirenz 600 mg at bedtime (N = 282)
Slovenian: efavirenz 600 mg pred spanjem (N = 282)
English: DUTREBIS should be used in combination with other active anti-retroviral therapy (ART) (see
Slovenian: Zdravilo DUTREBIS je treba uporabljati v kombinaciji z drugimi protiretrovirusnimi zdravili (glejte
English: Studies in patients with renal impairment show lamivudine elimination is affected by renal dysfunction.
Slovenian: Študije pri bolnikih z okvaro ledvic kažejo, da moteno delovanje ledvic vpliva na izločanje lamivudina.
English: DUTREBIS is an antiretroviral medicine used to treat infection with human immunodeficiency virus (HIV).
Slovenian: Zdravilo DUTREBIS je protiretrovirusno zdravilo, ki ga uporabljamo za zdravljenje okužbe z virusom humane imunske pomanjkljivosti (HIV).
English: The safety profile of DUTREBIS is based on the safety data from the individual components of DUTREBIS (lamivudine
Slovenian: Varnostni profil zdravila DUTREBIS temelji na podatkih o varnosti vsake od obeh posameznih učinkovin zdravila DUTREBIS
English: • inflammation of liver (hepatitis); When hepatitis causes symptoms, they can include: belly pain; nausea and vomiting; not feeling hungry; jaundice, which is when the skin or
Slovenian: • vnetje jeter (hepatitis); če hepatitis povzroči simptome, so med njimi lahko bolečine v trebuhu, siljenje na bruhanje in bruhanje, pomanjkanje občutka lakote, zlatenica (porumenelost kože ali očesnih beločnic)
English: Patients co-infected with hepatitis C and treated with alpha interferon and ribavirin may constitute a special risk.
Slovenian: Še posebej ogroženi so lahko bolniki, sočasno okuženi z virusom hepatitisa C in zdravljeni z interferonom alfa in ribavirinom.
English: STARTMRK (multi-centre, randomised, double-blind, active-control study) evaluated the safety and anti-retroviral activity of raltegravir 400 mg twice daily vs. efavirenz 600 mg at bedtime, in a combination with emtricitabine (+) tenofovir, in treatment-naïve HIV-infected patients with HIV RNA > 5,000 copies/ml.
Slovenian: V študiji STARTMRK (multicentrični, randomizirani, dvojno slepi, z zdravilno učinkovino nadzorovani študiji) so ocenjevali varnost in protiretrovirusno delovanje 400 mg raltegravirja dvakrat na dan v primerjavi s 600 mg efavirenza pred spanjem v kombinaciji z emtricitabinom (+) tenofovirjem pri še nezdravljenih bolnikih, okuženih s HIV in HIV RNA > 5.000 kopij/ml.
English: Less potent inducers (e.g., efavirenz, nevirapine, etravirine, rifabutin, glucocorticoids, St. John's wort, pioglitazone) may be used with DUTREBIS.
Slovenian: Z zdravilom DUTREBIS se lahko uporablja manj močne induktorje (npr. efavirenz, nevirapin, etravirin, rifabutin, glukokortikoide, šentjanževko, pioglitazon).
English: Because the extent to which DUTREBIS may be dialyzable is unknown, dosing before a dialysis session should be avoided (see sections 4.2 and 5.2).
Slovenian: Ker obseg izločanja zdravila DUTREBIS pri dializi ni znan, se je treba izogibati zaužitju zdravila pred dializo (glejte poglavji 4.2 in 5.2).
English: Placebo + OBT (N = 237)
Slovenian: placebo + OBT
English: Your doctor has prescribed DUTREBIS to help control your HIV infection.
Slovenian: Zdravnik vam je predpisal zdravilo DUTREBIS, da bi zdravilo pomagalo obvladovati okužbo z
English: DUTREBIS should not be used in children below 6 years of age or in patients weighing less than 30 kg due to weight based dosing requirements in this patient population.
Slovenian: Zdravila DUTREBIS se ne sme uporabljati pri otrocih, mlajših od 6 let, ali pri bolnikih s telesno maso manj kot 30 kg, ker je treba odmerek v tej populaciji bolnikov določiti glede na telesno
English: Interaction studies with these agents have only
Slovenian: Študije medsebojnega delovanja s tema učinkovinama so izvedli le pri odraslih.
English: For patients co-infected with hepatitis who are being treated with DUTREBIS and subsequently become pregnant, consideration should be given to the possibility of a recurrence of hepatitis on discontinuation of DUTREBIS.
Slovenian: Pri bolnicah, ki so hkrati okužene s hepatitisom, prejemajo zdravilo DUTREBIS in zanosijo, je treba upoštevati možnost ponovitve hepatitisa po prenehanju uporabe zdravila DUTREBIS.
English: Rash occurred more commonly in treatment-experienced patients receiving regimens containing raltegravir + darunavir compared to patients receiving raltegravir without darunavir or darunavir
Slovenian: Izpuščaj se je pogosteje pojavil pri predhodno že zdravljenih bolnikih, ki so prejemali zdravilo raltegravir in darunavir, kot pri tistih, ki so prejemali raltegravir brez darunavirja ali darunavir brez